Association of Intrapatient Variability of Tacrolimus Concentration With Early Deterioration of Chronic Histologic Lesions in Kidney Transplantation
Open Access
- 22 May 2019
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Transplantation Direct
- Vol. 5 (6), e455
- https://doi.org/10.1097/txd.0000000000000899
Abstract
Background. High intrapatient variability (IPV) of tacrolimus (Tac) is increasingly recognized as a risk factor for poor graft outcomes in kidney transplantation. The timing of onset of its impact on kidney histologic lesions has not been investigated. Methods. We analyzed the adverse effect of Tac IPV using the coefficient of variability from 6 to 12 months posttransplantation on long-term outcomes in a cohort of 671 kidney recipients and on the evolution of chronic histologic lesions in a cohort of 212 recipients for whom paired protocol biopsies at 10 days and 1 year were available. Results. High IPV of Tac (cutoff value of coefficient of variability = median of 20.5%) was associated with an increased risk of graft loss (hazard ratio, 3.28; 95% confidence interval, 1.090–9.849; P = 0.035) in the entire cohort. At 1 year, the high Tac IPV group showed a significantly deteriorated chronicity score (F = 5.912, P = 0.016) compared with the low Tac IPV group in the Histology cohort after controlling for the 10-day scores. In a multivariate analysis, a high IPV of Tac was predictive of the chronicity score (odds ratio, 1.91; 95% confidence interval, 0.215–1.075; P = 0.003) at 1 year posttransplant. Conclusions. These data indicate that high IPV of Tac is associated with early deterioration of chronic histologic lesions as well as poorer long-term outcomes. Large prospective studies of Tac IPV usage as a clinical monitoring tool are needed in the future.Keywords
This publication has 47 references indexed in Scilit:
- Conversion of Twice-Daily Tacrolimus to Once-Daily Tacrolimus Formulation in Stable Pediatric Kidney Transplant Recipients: Pharmacokinetics and EfficacyAmerican Journal of Transplantation, 2013
- Randomized Trial of Mycophenolate Mofetil Versus Enteric-Coated Mycophenolate Sodium in Primary Renal Transplantation With Tacrolimus and Steroid Avoidance: Four-Year AnalysisTransplantation, 2011
- Long-Term Renal Allograft Survival in the United States: A Critical ReappraisalAmerican Journal of Transplantation, 2011
- Optimized Tacrolimus Therapy in the Early Stage after Renal TransplantationJournal of the Korean Surgical Society, 2010
- Immunosuppressive Drugs in Kidney TransplantationDrugs, 2009
- Banff 07 Classification of Renal Allograft Pathology: Updates and Future DirectionsAmerican Journal of Transplantation, 2008
- Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial dataBMJ, 2005
- Kidney Allograft Fibrosis and Atrophy Early After Living Donor TransplantationAmerican Journal of Transplantation, 2005
- Long-Term Renal Allograft Survival: Have we Made Significant Progress or is it Time to Rethink our Analytic and Therapeutic Strategies?American Journal of Transplantation, 2004
- Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and p-glycoprotein correlate with dose requirementTransplantation, 2002